Qsymia as an Adjunct to Surgical Therapy in the Superobese

Obesity Clinical Trial

Official title:

Qsymia as an Adjunct to Surgical Therapy in the Superobese

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02301416
• Other study ID #: IRB00027047
• Status: Completed
• Phase: Phase 2
• Start date: December 2014
• Est. completion date: June 27, 2018

Study information

• Verified date: November 2018
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese individuals planning to undergo weight loss surgery. Individuals taking the medication before and after surgery will be compared to historical controls who had surgery without taking the medication.

Description:

While there is obvious focus on the obesity epidemic that affects approximately one-third of the U.S. population, one subgroup within the epidemic remains on the fringe of scientific study and effective treatment options. The super obese patient, in this instance defined as those with a BMI ≥ 50 kg/m2, presents a difficult treatment challenge in managing this level of obesity. While bariatric surgery, including Roux-en-Y gastric bypass and biliopancreatic diversion with duodenal switch, have been shown to be effective in severe obesity (BMI ≥ 40 kg/m2), the risks involved with surgical intervention in the super obese patient are high.

Qsymia provides a potential opportunity to develop an effective treatment plan that would be an adjunct to surgical intervention in the super obese patient. Use of Qsymia in addition to a low-calorie dietary prescription pre-operatively would effectively decrease weight prior to surgical intervention, lowering surgical risk to some extent. Additionally, if continued post-operatively, Qsymia as an adjunct to the post-surgical dietary plan would potentially extend the weight loss horizon so that the probability of the typical weight loss plateau at 12-18 months is decreased.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: June 27, 2018
• Est. primary completion date: June 27, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• BMI = 50 kg/m2

• Determined to be a good candidate for surgery based on medical and psychological exam.

• Willing to participate in a 3-6 month medically supervised weight loss plan prior to surgery.

• Planning to remain in the reasonable vicinity of the Wake Forest Baptist Health - Weight Management Center for the duration of the study.

Exclusion Criteria:

• History of prior weight loss surgery (removal/conversion from band to sleeve will not be excluded)

• Pregnant (women of childbearing potential will complete a pregnancy test (blood draw) to make sure they are not pregnant at the time that they initiate the medication). Ongoing monitoring of pregnancy status is the responsibility of the patient and they are instructed as such in the consent form.

• Ongoing use of weight loss medication

• Contraindications to use of Qsymia, including pregnancy, history of glaucoma, unstable cardiac disease (unstable angina, recent heart attack or stroke (in the past 6 months), uncontrolled arrhythmia), hyperthyroidism, taking monoamine oxidase inhibitors (MAOIs) or allergy to either topiramate or sympathomimetic amines like phentermine.

Related Conditions & MeSH terms

• Bariatric Surgery Procedures
• Metabolic Surgery
• Obesity
• Weight Loss

Intervention

Drug:
• Phentermine/topiramate
Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.

Other:
• low calorie diet
The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.

Locations

Country	Name	City	State
United States	Wake Forest Baptist Health	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	VIVUS, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Patients Who do Not Meet the Criteria to Move Forward With Roux en Y Gastric Bypass (RYGB)	Proportion of patients who do not meet the criteria to move forward with a second surgical procedure following an initial procedure plus the medication Qsymia. The criteria that suggest RYGB is indicated are: 1) BMI of 40 or greater or 2) BMI of 35-39.9 with poorly controlled co-morbidities.	24 months post-operatively
Secondary	Percent Weight Change	Percent weight loss achieved before and after surgery while taking the medication, Qsymia.	Pre-operatively and 24 months post-operatively
Secondary	Body Mass Index	Resulting body mass index	24 months post-operatively
Secondary	Percent Body Fat	Change in percent body fat	24 months post-operatively
Secondary	Resting Metabolic Rate	Resting metabolic rate via indirect calorimetry	24 months post-operatively
Secondary	Percent Weight Change	Percent weight loss achieved before and after surgery while taking the medication, Qsymia.	Pre-operatively and 12 months post-operatively
Secondary	Percent Weight Change	Percent weight loss achieved before and after surgery while taking the medication, Qsymia.	Pre-operatively and 6 months post-operatively
Secondary	Percent Weight Change	Percent weight loss achieved before and after surgery while taking the medication, Qsymia.	Pre-operatively and 3 months post-operatively
Secondary	Body Mass Index	Resulting body mass index	12 months post-operatively
Secondary	Body Mass Index	Resulting body mass index	6 months post-operatively
Secondary	Body Mass Index	Resulting body mass index	3 months post-operatively
Secondary	Percent Body Fat	Change in percent body fat	12 months post-operatively
Secondary	Percent Body Fat	Change in percent body fat	6 months post-operatively
Secondary	Percent Body Fat	Change in percent body fat	3 months post-operatively
Secondary	Resting Metabolic Rate	Resting metabolic rate via indirect calorimetry	12 months post-operatively
Secondary	Resting Metabolic Rate	Resting metabolic rate via indirect calorimetry	6 months post-operatively
Secondary	Resting Metabolic Rate	Resting metabolic rate via indirect calorimetry	3 months post-operatively